The use of a somatostatin analog in the treatment of refractory hypotension after cardiopulmonary bypass

Egener, Todd H.; Comunale, Mark E.; Leckie, Robert S.

doi:10.1016/1053-0770(92)90015-y

Cited by 7 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Patients undergoing aortocoronary bypass operations have been shown to exhibit increases of more than 6 times in circulating AVP levels during and as long as 12 hours after CPB, 15 to levels often exceeding 100 pg/mL. 13 However, a few authors have documented cases of post-CPB AVP deficiency manifesting as diabetes insipidus, 16,17 whereas others have described a clinical vasodilatory syndrome responsive to such agents as octreotide 18 and angiotensin II. 19 In our study of 145 cardiac surgical patients, the incidence of vasodilatory shock in the early post-CPB period was 8%, although this syndrome was significantly more common (27%) among patients with low ejection fraction.…”

Section: Discussionmentioning

confidence: 99%

Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent

Argenziano

Chen

Choudhri

et al. 1998

The Journal of Thoracic and Cardiovascular Surgery

337

218

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent

Argenziano

Chen

Choudhri

et al. 1998

The Journal of Thoracic and Cardiovascular Surgery

337

218

View full text Add to dashboard Cite

show abstract

“…It has been reported by some investigators to cause arterial and venous vasoconstriction 29 and to increase peripheral vascular resistance. 21,22,24,30 Whereas some believe these effects are secondary to hormonal modulation (namely, inhibiting the release of various vasoactive peptides such as glucagon, vasoactive intestinal peptide, and cholecystokinin), 13,21,31 others propose a direct vasoconstrictive effect of octreotide on the vasculature. 32 In this study, we have shown that octreotide leads to significant reduction in FBF.…”

Section: Discussionmentioning

confidence: 99%

“…There are a few reports suggesting that the effect of octreotide may not be limited to the splanchnic circulation, but that octreotide also has peripheral effects that are evident by increased MAP and peripheral vascular resistance in experimental animals and patients receiving octreotide. [21][22][23][24] Moreover, there is evidence suggesting that octreotide may be locally vasoactive. In vitro, a vasoconstrictive effect has been shown in canine cerebral arteries.…”

mentioning

confidence: 99%

Local arterial vasoconstriction induced by octreotide in patients with cirrhosis

et al. 2000

View full text Add to dashboard Cite

Peripheral vasodilation initiates the hyperdynamic circulation in cirrhosis. Somatostatin and its analogues, such as octreotide, have a vasoconstrictive effect in cirrhotic patients and experimental animals with portal hypertension. The exact mechanism of octreotide-induced vasoconstriction remains unknown. To investigate whether octreotide produces vasoconstriction through suppression of vasodilatory peptides, such as glucagon, or through a local effect, we evaluated the effect of an intra-arterial dose on forearm blood flow (FBF), while measuring systemic glucagon levels. FBF was measured in 10 cirrhotic patients by venous occlusion plethysmography. The brachial artery of the nondominant arm was catheterized, and vasoactive drugs were administered: methacholine 4 g/min; octreotide 20 g/h, and octreotide 20 g/h ؉ methacholine 4 g/min. Each infusion, lasting 5 minutes, was followed by saline for washout. FBF was measured in both arms during the last minute of each infusion and at the end of washout, with the uninfused arm acting as the control. Nitrates and nitrites, octreotide, and glucagon blood levels were determined at baseline and after each infusion. Percent change in flow (%⌬) was obtained by comparing the flow during drug administration to that during the preceding saline infusion. Saline infusion did not alter FBF, but octreotide infusion resulted in a 34% ؎ 7.7 (P F .005) reduction in FBF in the infused arm. FBF in the control arm was unchanged despite a significant decrease in systemic glucagon levels. Methacholine infusion increased FBF around 300%, which was not altered by the concomitant infusion of octreotide. Octreotide has a local vasoconstrictive effect that seems nitric oxide (NO)-independent. Octreotide probably has a facilitating effect over vasoconstrictors increased in chronic liver diseases. (HEPATOLOGY 2000;31:572-576.)Chronic peripheral vasodilation is the hallmark hemodynamic abnormality in portal hypertension, which accounts for several important complications of cirrhosis. 1 This state (characterized by low mean arterial pressure [MAP], increased cardiac output, and increased regional blood flow) has been shown to be, at least in part, caused by increased production of the endothelial vasodilator nitric oxide (NO). [2][3][4][5] Studies of the natural history in patients with cirrhosis clearly illustrate that one of the main predictors of survival in patients with cirrhosis and ascites is the MAP. A low MAP that reflects a state of peripheral arterial vasodilation was directly associated with poor survival rate. 6 As a result, there is an interest in drugs that could modify this state without inducing untoward effects. Octreotide, a long-acting analogue of somatostatin, 7 was introduced for clinical use in patients with cirrhosis and variceal hemorrhage in the early 1990s. 8 Its initial clinical use was mostly based on data about the beneficial effect of somatostatin, its naturally occurring hormone, in this clinical setting. The mechanism by which the systemic administration of somat...

show abstract

Somatostatin-mediated vasoconstriction in human saphenous vein

Dimech

Doyle

Latimer

et al. 1994

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

The use of a somatostatin analog in the treatment of refractory hypotension after cardiopulmonary bypass

Cited by 7 publications

References 8 publications

Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent

Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent

Local arterial vasoconstriction induced by octreotide in patients with cirrhosis

Somatostatin-mediated vasoconstriction in human saphenous vein

Contact Info

Product

Resources

About